The Progress in the Treatment of Persistent Pulmonary Hypertension in Neonatal

Fang Sai,Du Lizhong
DOI: https://doi.org/10.3877/cma.j.issn.2096-1537.2019.03.012
2019-01-01
Abstract:Persistent pulmonary hypertension of neonatal (PPHN) refers to the continuous increase of pulmonary vascular resistance after birth, which causes the abnormal development from fetal circulation to ″adult″ type circulatory and the subsequent right to left shunt through atrial septum or arterial duct. Clinical symptoms include severe hypoxemia and even respiratory failure. PPHN can be seen in the congenital dysplasia of the lung, as well as in the substantial lung diseases. The incidence of the disease is around 0.2%, and mortality about 10%. In addition to the treatment of the underlying disease, timely and effective treatments like respiratory support and vasoactive drugs can significantly reduce the incidence and mortality of the disease. This article summarizes the current treatment progress in persistent pulmonary hypertension of neonatal, and provides useful information for clinicians. Key words: Neonates; Persistent pulmonary hypertension of neonatal; Treatment progress
What problem does this paper attempt to address?